Desmopressin intranasal - CPX Pharmaceuticals/Serenity Pharmaceuticals

Drug Profile

Desmopressin intranasal - CPX Pharmaceuticals/Serenity Pharmaceuticals

Alternative Names: AV002 - Avadel Pharmaceuticals; Desmopressin acetate; Intranasal desmopressin - Serenity Pharmaceuticals; Noctiva; SER 120; SER-120 - CPX Pharmaceuticals/Serenity Pharmaceuticals

Latest Information Update: 12 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator CPEX Pharmaceuticals; Serenity Pharmaceuticals Corporation
  • Developer Serenity Pharmaceuticals Corporation
  • Class Antidiuretics; Antihaemorrhagics; Hormones; Urologics; Vasoconstrictors; Vasopressins
  • Mechanism of Action Vasopressin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Registered Nocturia

Most Recent Events

  • 05 Oct 2017 Avadel Pharmaceuticals intends to launch desmopressin intranasal in the second quarter of 2018
  • 05 Oct 2017 Efficacy data from the subset analysis of the phase III trials in Nocturia released Avadel Pharmaceuticals
  • 05 Sep 2017 Serenity Pharmaceuticals and Avadel Pharmaceuticals enter a licensing agreement to develop and commercialise Desmopressin intranasal in USA and Canada
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top